EPHA2 and neoplasm: In vitro experiments demonstrated that both CAR-T cells could be activated by EphA2-positive tumor cells, with EphA2-a CAR-T exhibiting significantly higher tumor-killing efficiency compared to EphA2-b CAR-T.